ReviewERJ open research2020
ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly.
Review in ERJ open research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Qingke Pingchuan granules as adjuvant therapy for acute exacerbation of chronic obstructive pulmonary disease, acute exacerbation asthma, and acute bronchitis: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- NLBK alleviates airway remodeling in COPD by inhibiting RXRA-mediated transcription of PLA2G2A.American journal of translational research · 2025Article
- ERS International Congress 2023: highlights from the Airway Diseases Assembly.ERJ open research · 2024Article
- Do Patients with Bronchiectasis Have an Increased Risk of Developing Lung Cancer? A Systematic Review.Life (Basel, Switzerland) · 2023Review
- Current developments and future directions in COPD.European respiratory review : an official journal of the European Respiratory Society · 2020Article
- Could Arachidonic Acid-Derived Pro-Resolving Mediators Be a New Therapeutic Strategy for Asthma Therapy?Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Respiratory Society (ERS) International Congress 2019 in Madrid, Spain, was a platform for scientific discussion of the highest quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory field. This article discusses some of the high-quality research studies presented at that Congress, with a focus on airway diseases, including asthma, COPD, small airways, bronchiectasis and cough, presented through the Airway Diseases, Asthma and COPD Assembly (Assembly 5) of the ERS. The authors establish the key take-home messages of these studies, compare their findings and place them into context of current understanding.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.